JHEP reports : innovation in hepatology · 2026
Integrative multi-omics analysis identifies stellate cell-derived complement component 7 as a predictor of fibrosis and liver-related events in MASLD.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kondo Shohei, Kimura Takefumi, Iwadare Takanobu, Taufeeq Mohammad, Miwa Takao, Fujimori Naoyuki, Nakajima Tomoyuki, Wakabayashi Shun-Ichi, Okumura Taiki, Kobayashi Hiroyuki, Yamashita Yuki, Isogai Satsuki, Yamazaki Tomoo, Iwaya Mai, Uehara Takeshi, Umemura Takeji, Choudhary Saket, Schnabl Bernd, Jain Shanu, Tanaka Naoki
Аннотация
BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health burden, with advanced fibrosis and liver-related events (LREs) being key prognostic factors. However, existing non-invasive biomarkers insufficiently capture fibrosis severity and LRE risk. We aim at identifying a mechanistically grounded biomarker for clinical risk stratification.
METHODS: We performed an integrative multi-omics analysis using publicly available hepatic transcriptomic and plasma proteomic datasets together with in-house spatial transcriptomic analyses, followed by validation in three MASLD cohorts: biopsy-confirmed Japanese (n = 430), vibration-controlled transient elastography-based (n = 120), and UK Biobank (n = 4,486) cohorts. LRE risk was assessed using Kaplan-Meier and Cox regression analyses. Single-nucleus RNA sequencing, in situ hybridization, and in vitro assays using hepatic stellate cells (HSCs) were performed to assess molecular localization and functional relevance.
RESULTS: Complement component 7 (C7) was consistently identified as the top candidate. Spatial transcriptomics and in situ hybridization localized C7 expression to activated HSCs within fibrotic regions. Serum C7 levels strongly correlated with fibrosis stage and liver stiffness. A threshold ≥140 μg/ml predicted significantly higher LRE risk and remained independently predictive (hazard ratio 4.54, 95% confidence interval 1.49-13.82). In area under the receiver operating characteristic curve analysis, C7 outperformed FIB-4, autotaxin, AST-to-platelet ratio index (APRI), FibroScan-AST (FAST), and AST-to-ALT ratio (AAR), with AUROCs of 0.90 vs. 0.85, 0.84, 0.77, 0.75, 0.67, respectively). External validation in UK Biobank supported these findings. Spatial module-score analyses linked C7-enriched regions to extracellular matrix/HSC-related fibrogenic programs and progenitor/ductular reaction signatures. C7 knockdown in LX-2 cells suppressed extracellular matrix genes including LAMA2, LAMB1, and COL6A3.
CONCLUSIONS: C7 is a mechanistically supported, non-invasive biomarker that surpasses conventional indices in predicting fibrosis and LREs in MASLD. These findings highlight complement-mediated fibrogenesis and C7 as a potential tool for clinical risk stratification.
IMPACT AND IMPLICATIONS: This study identifies complement component 7 (C7) as a non-invasive biomarker associated with fibrosis severity and liver-related events in MASLD through an integrative multi-omics approach. C7 was linked to HSC-rich fibrotic niches, extracellular matrix remodeling, and future liver-related risk, with external validation in the UK Biobank cohort. These findings suggest that serum C7 may improve risk stratification by capturing both fibrosis burden and clinically relevant disease progression in MASLD.
METHODS: We performed an integrative multi-omics analysis using publicly available hepatic transcriptomic and plasma proteomic datasets together with in-house spatial transcriptomic analyses, followed by validation in three MASLD cohorts: biopsy-confirmed Japanese (n = 430), vibration-controlled transient elastography-based (n = 120), and UK Biobank (n = 4,486) cohorts. LRE risk was assessed using Kaplan-Meier and Cox regression analyses. Single-nucleus RNA sequencing, in situ hybridization, and in vitro assays using hepatic stellate cells (HSCs) were performed to assess molecular localization and functional relevance.
RESULTS: Complement component 7 (C7) was consistently identified as the top candidate. Spatial transcriptomics and in situ hybridization localized C7 expression to activated HSCs within fibrotic regions. Serum C7 levels strongly correlated with fibrosis stage and liver stiffness. A threshold ≥140 μg/ml predicted significantly higher LRE risk and remained independently predictive (hazard ratio 4.54, 95% confidence interval 1.49-13.82). In area under the receiver operating characteristic curve analysis, C7 outperformed FIB-4, autotaxin, AST-to-platelet ratio index (APRI), FibroScan-AST (FAST), and AST-to-ALT ratio (AAR), with AUROCs of 0.90 vs. 0.85, 0.84, 0.77, 0.75, 0.67, respectively). External validation in UK Biobank supported these findings. Spatial module-score analyses linked C7-enriched regions to extracellular matrix/HSC-related fibrogenic programs and progenitor/ductular reaction signatures. C7 knockdown in LX-2 cells suppressed extracellular matrix genes including LAMA2, LAMB1, and COL6A3.
CONCLUSIONS: C7 is a mechanistically supported, non-invasive biomarker that surpasses conventional indices in predicting fibrosis and LREs in MASLD. These findings highlight complement-mediated fibrogenesis and C7 as a potential tool for clinical risk stratification.
IMPACT AND IMPLICATIONS: This study identifies complement component 7 (C7) as a non-invasive biomarker associated with fibrosis severity and liver-related events in MASLD through an integrative multi-omics approach. C7 was linked to HSC-rich fibrotic niches, extracellular matrix remodeling, and future liver-related risk, with external validation in the UK Biobank cohort. These findings suggest that serum C7 may improve risk stratification by capturing both fibrosis burden and clinically relevant disease progression in MASLD.